September 6, 2024

Connect Biotech Scales Back in China, Reassesses Strategy for Asthma Drug to Compete with Dupixent

8 months ago talkbio0Tagged asthma drug strategy, biotech, China, Connect (action), Dupixent Rival, Industry

Connect Biotech, China workforce reduction, Dupixent rival, asthma drug strategy, biotech industry

Travere Therapeutics Secures Full FDA Approval for FILSPARI in Treating IgA Nephropathy

8 months ago talkbio0Tagged Approved, FILSPARI, IGA Glomerulonephritis, Kidney Diseases, United States Food and Drug Administration

FILSPARI, IgA Nephropathy, FDA Approval, Kidney Disease, Travere Therapeutics

Crestone’s CRS3123 Shows Superior Efficacy in Curing C. difficile Infections and Preventing Recurrence Compared to Vancomycin in Phase 2 Trial

8 months ago talkbio0Tagged Antibiotics, C. difficile, CRS3123, Effectiveness, Phase 2 clinical trial, prevention of later incidences of a disorder, vancomycin

C. difficile infections, CRS3123, Vancomycin, Phase 2 clinical trial, Antibiotic efficacy, Recurrence prevention

OrsoBio Secures $67 Million in Funding for Next-Generation Obesity Treatments

8 months ago talkbio0Tagged Eli, Eli Lilly, Metabolic Diseases, Obesity, OrsoBio, Series B, weight loss medicines

OrsoBio, obesity drugs, Eli Lilly, Series B funding, weight loss medicines, metabolic disorders

AOA’s ‘Eye Deserve More’ Campaign Highlights the Unmatched Capabilities of the Human Eye

8 months ago talkbio0Tagged Americas Ethnicity, Blindness, Comprehensive Eye Care, Digital Eye Strain, Eye, Eye Deserve, Homo sapiens, Optometric Association, Optometry, The Eye

American Optometric Association, Eye Deserve More, The Eye, Human Eye, Eye Health, Comprehensive Eye Care, Digital Eye Strain, Vision Loss, Optometry

ImmunityBio Trims Workforce Despite Recent FDA Approval for Anktiva

8 months ago talkbio0Tagged Anktiva, Approved, Cancer Therapeutic Procedure, Financial Stress, ImmunityBio, United States Food and Drug Administration, Urinary Bladder

ImmunityBio, Anktiva, FDA approval, layoffs, financial challenges, bladder cancer treatment

ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges

8 months ago talkbio0Tagged Agonist, Anktiva, Approved, Cancer Therapeutic Procedure, financial troubles, ImmunityBio, Immunotherapy, Interleukin-15, United States Food and Drug Administration

ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

8 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis

8 months ago talkbio0Tagged Biotechnology, capsid discovery, gene therapy, Huntington Disease, Novartis, Spinal Muscular Atrophy, Tracer

Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration

Eli Lilly Partners with Genetic Leap in $409 Million AI-Driven Drug Development Deal

8 months ago talkbio0Tagged AI-powered, Eli, Eli Lilly, Genetic Leap, oligonucleotide therapy, pharmaceutical partnership

Eli Lilly, Genetic Leap, AI-powered drug deal, oligonucleotide therapy, pharmaceutical partnership